Format

Send to

Choose Destination
Front Oncol. 2019 Jun 18;9:516. doi: 10.3389/fonc.2019.00516. eCollection 2019.

TICRR Contributes to Tumorigenesis Through Accelerating DNA Replication in Cancers.

Yu Q1,2,3,4,5, Pu SY1,2,3,4, Wu H1,2,3,4, Chen XQ1,2,3,4, Jiang JJ1,2,3,4, Gu KS1,2,3,4,5, He YH1,2,3,4, Kong QP1,2,3,4.

Author information

1
State Key Laboratory of Genetic Resources and Evolution/Key Laboratory of Healthy Aging Research of Yunnan Province, Kunming Institute of Zoology, The Chinese Academy of Sciences, Kunming, China.
2
Center for Excellence in Animal Evolution and Genetics, Chinese Academy of Sciences, Kunming, China.
3
Kunming Key Laboratory of Healthy Aging Study, Kunming, China.
4
KIZ/CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming, China.
5
Kunming College of Life Science, University of Chinese Academy of Sciences, Beijing, China.

Abstract

DNA replication is precisely regulated in cells and its dysregulation can trigger tumorigenesis. Here we identified that the TOPBP1 interacting checkpoint and replication regulator (TICRR) mRNA level was universally and highly expressed in 15 solid cancer types. Depletion of TICRR significantly inhibited tumor cell growth, colony formation and migration in vitro, and strikingly inhibited tumor growth in the xenograft model. We reveal that knockdown of TICRR inhibited not only the initiation but also the fork progression of DNA replication. Suppression of DNA synthesis by TICRR silencing caused DNA damage accumulation, subsequently activated the ATM/CHK2 dependent p53 signaling, and finally induced cell cycle arrest and apoptosis at least in p53-wild cancer cells. Further, we show that a higher TICRR level was associated with poorer overall survival (OS) and disease free survival (DFS) in multiple cancer types. In conclusion, our study shows that TICRR is involved in tumorigenesis by regulating DNA replication, acting as a common biomarker for cancer prognosis and could be a promising target for drug-development and cancer treatment.

KEYWORDS:

ATM/CHK2; DNA replication; TICRR; p53 pathway; proliferation; tumorigenesis

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center